Afatinib Reduces STAT6 Signaling of Host ARPE-19 Cells Infected with Toxoplasma gondii
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Specific gene expressions of host cells by spontaneous STAT6 phosphorylation are major strategy for the survival of intracellular Toxoplasma gondii against parasiticidal events through STAT1 phosphorylation by infection provoked IFN-γ. We determined the effects of small molecules of tyrosine kinase inhibitors (TKIs) on the growth of T. gondii and on the relationship with STAT1 and STAT6 phosphorylation in ARPE-19 cells. We counted the number of T. gondii RH tachyzoites per parasitophorous vacuolar membrane (PVM) after treatment with TKIs at 12-hr intervals for 72 hr. The change of STAT6 phosphorylation was assessed via western blot and immunofluorescence assay. Among the tested TKIs, Afatinib (pan ErbB/EGFR inhibitor, 5 µM) inhibited 98.0% of the growth of T. gondii, which was comparable to pyrimethamine (5 µM) at 96.9% and followed by Erlotinib (ErbB1/EGFR inhibitor, 20 µM) at 33.8% and Sunitinib (PDGFR or c-Kit inhibitor, 10 µM) at 21.3%. In the early stage of the infection (2, 4, and 8 hr after T. gondii challenge), Afatinib inhibited the phosphorylation of STAT6 in western blot and immunofluorescence assay. Both JAK1 and JAK3, the upper hierarchical kinases of cytokine signaling, were strongly phosphorylated at 2 hr and then disappeared entirely after 4 hr. Some TKIs, especially the EGFR inhibitors, might play an important role in the inhibition of intracellular replication of T. gondii through the inhibition of the direct phosphorylation of STAT6 by T. gondii.
Abstract
Specific gene expressions of host cells by spontaneous STAT6 phosphorylation are major strategy for the survival of intracellular Toxoplasma gondii against parasiticidal events through STAT1 phosphorylation by infection provoked IFN-γ. We determined the effects of small molecules of tyrosine kinase inhibitors (TKIs) on the growth of T. gondii and on the relationship with STAT1 and STAT6 phosphorylation in ARPE-19 cells. We counted the number of T. gondii RH tachyzoites per parasitophorous vacuolar membrane (PVM) after treatment with TKIs at 12-hr intervals for 72 hr. The change of STAT6 phosphorylation was assessed via western blot and immunofluorescence assay. Among the tested TKIs, Afatinib (pan ErbB/EGFR inhibitor, 5 µM) inhibited 98.0% of the growth of T. gondii, which was comparable to pyrimethamine (5 µM) at 96.9% and followed by Erlotinib (ErbB1/EGFR inhibitor, 20 µM) at 33.8% and Sunitinib (PDGFR or c-Kit inhibitor, 10 µM) at 21.3%. In the early stage of the infection (2, 4, and 8 hr after T. gondii challenge), Afatinib inhibited the phosphorylation of STAT6 in western blot and immunofluorescence assay. Both JAK1 and JAK3, the upper hierarchical kinases of cytokine signaling, were strongly phosphorylated at 2 hr and then disappeared entirely after 4 hr. Some TKIs, especially the EGFR inhibitors, might play an important role in the inhibition of intracellular replication of T. gondii through the inhibition of the direct phosphorylation of STAT6 by T. gondii.
참고문헌 (28)
- Holland GN, "Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease", Am J Ophthalmol, 135, pp.973~988 (2003)
- Subauste CS, "Review of the series “Disease of the year 2011: toxoplasmosis” pathophysiology of toxoplasmosis", Ocul Immunol Inflamm, 19, pp.297~306 (2011)
- Tenter AMA, "Toxoplasma gondii: from animals to humans", Int J Parasitol, 30, pp.1217~1258 (2000)
- McCannel CAC, "Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group", Am J Ophthalmol, 121, pp.35~46 (1996)
- Holland GN, "An update on current practices in the management of ocular toxoplasmosis", Am J Ophthalmol, 134, pp.102~114 (2002)
- Silveira C, "The effect of long-term intermittent trimethoprim", sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis, 2002, pp.134, 41~46
- John DT, "Markell and Voge’s Medical Parasitology", pp.139~149 (2006), Elsevier
- Sharma R, "Stevens-Johnson syndrome following sulfadiazine, Tri-sulfose and sulfatriad therapy", J Assoc Physicians India, 13, pp.727~730 (1965)
- Carrión-Carrión C, "Fatal Stevens-Johnson syndrome in an AIDS patient treated with sulfadiazine", Ann Pharmacother, 33, pp.379~380 (1999)
- Hajj H, "Inverted topology of the Toxoplasma gondii ROP5 rhoptry protein provides new insights into the association of the ROP2 protein family with the parasitophorous vacuole membrane", Cell Microbiol, 9, pp.54~64 (2007)
- Hajj H, "The ROP2 family of Toxoplasma gondii rhoptry proteins: proteomic and genomic characterization and molecular modeling", Proteomics, 6, pp.5773~5784 (2006)
- 안혜진, "IL-4 Independent Nuclear Translocalization of STAT6 in HeLa Cells by Entry of Toxoplasma gondii", The Korean Journal of Parasitology, 47(2), pp.117~124 (2009), 대한기생충학ㆍ열대의학회
- 안혜진, "Seroprevalence of Toxoplasmosis in the Residents of Cheorwon-gun, Gangwon-do, Korea", The Korean Journal of Parasitology, 50(3), pp.225~227 (2012), 대한기생충학ㆍ열대의학회
- Zhang J, "Targeting cancer with small molecule kinase inhibitors", Nat Rev Cancer, 9, pp.28~39 (2009)
- Cruzalegui F, "Protein kinases: from targets to anti-cancer drugs", Ann Pharm Fr, 68, pp.254~259 (2010)
- Sun K, "Screening for inhibition of the Vibrio cholera VipA-VipB interaction identifies small molecule compounds active against type VI secretion", Antimicrob Agents Chemother, 58, pp.4123~4130 (2014)
- Lepri S, "Optimization of small molecule inhibitors of influenza virus polymerase : from thiophene-3-carboxamide to polyamido scaffolds", J Med Chem, 57, pp.4337~4350 (2014)
- Qi WX, "Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis", Asian Pac J Cancer Prev, 13, pp.5177~5182 (2012)
- Bowles DW, "Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer", Drugs Today, 49, pp.523~535 (2013)
- Dranitsaris G, "Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma : a systematic review and indirect comparison of safety and efficacy", J Cancer Res Clin Oncol, 139, pp.1917~1926 (2013)
- Wei F, "Protein kinases of Toxoplasma gondii: functions and drug targets", Parasitol Res, 112, pp.2121~2129 (2013)
- Caldas LA, "Calcium ionophore-induced egress of Toxoplasma gondii shortly after host cell invasion", Vet Parasitol, 147, pp.210~220 (2007)
- Ferreira S, "Protein phosphorylation during the process of interaction of Toxoplasma gondii with host cells", J Submicrosc Cytol Pathol, 35, pp.245~252 (2003)
- Caldas LA, "The effect of kinase, actin, myosin and dynamin inhibitors on host cell egress by Toxoplasma gondii", Parasitol Int, 62, pp.475~482 (2013)
- Ahn HJ, "STAT6 activation by Toxoplasma gondii infection induces the expression of Th2 C-C chemokine ligands and B clade serine protease inhibitors in macrophage", Parasitol Res, 105, pp.1445~1453 (2009)
- Stark GR, "The JAK-STAT pathway at twenty", Immunity, 36, pp.503~514 (2012)
- Kiu H, "Biology and significance of the JAK", STAT signalling pathway, 2012, pp.30, 88~106
- Laliberte J, "Host cell manipulation by the human pathogen Toxoplasma gondii", Cell Mol Life Sci, 65, pp.1900~1915 (2008)